A systematic review of opioid effects on the hypogonadal axis of cancer patients
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Purpose Opioids are the mainstay of analgesic therapy in patients with cancer-related pain. While many of the side effects of opioids are well documented, the effect on the hypogonadal axis is less well understood. The aim of this systematic review is to examine the relationship between opioid therapy and hypogonadism in patients with cancer. Methods An electronic search of the following databases was undertaken: MEDLINE, Embase and CINAHL from 1974 to August 2013. To be eligible for inclusion, studies had to meet the following criteria: adult patients (>18 years) with cancer taking any opioid by any route for any duration, gonadal function measured and the relationship between opioid use and gonadal function examined. All potentially eligible papers were reviewed independently and data extracted using a pro forma. Results Four studies met the inclusion criteria. Due to the heterogeneous nature of the studies, it was not possible to amalgamate the results. Three studies suggested a relationship between opioid use and hypogonadism in patients with cancer. These studies also suggested this relationship to be dose dependent. There was evidence to suggest that hypogonadism was symptomatic and associated with reduced survival. One study showed no link between opioids and hypogonadism. Conclusions Studies conducted have suggested an association between opioids and hypogonadism in patients with cancer. This warrants further investigation. A longitudinal study examining the impact of…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 1×
“These include decreased energy, lack of motivation, depressed mood, poor concentration and memory and diminished physical performance [5].”
BackgroundInternational Association for the Study of Pain
Breivik, H. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00465-7 · Cited by 1,221
A validation study of the WHO method for cancer pain relief
Ventafridda, V., Tamburini, M., Caraceni, A., De Conno, F., & Naldi, F. (1987) · Cancer · doi:10.1002/1097-0142(19870215)59:4<850::aid-cncr2820590432>3.0.co;2-1 · Cited by 771
An international survey of cancer pain characteristics and syndromes
Caraceni, A., & Portenoy, R. K. (1999) · Pain · doi:10.1016/s0304-3959(99)00073-1 · Cited by 632
Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review
McNicol, E., Horowicz-Mehler, N., Fisk, R. A., Bennett, K., Gialeli-Goudas, M., Chew, P. W., Lau, J., & Carr, D. (2003) · The Journal of Pain · doi:10.1016/s1526-5900(03)00556-x · Cited by 466
Hypogonadism in men consuming sustained-action oral opioids
Daniell, H. W. (2002) · The Journal of Pain · doi:10.1054/jpai.2002.126790 · Cited by 401
Daniell, H. W. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.08.005 · Cited by 263 · cited 2×
“No association with time on opioid or type of opioid consumed was found in women with chronic non-malignant pain [23].”
BackgroundFunction of the Male Sex Organs in Heroin and Methadone Users
Cicero, T. J., Bell, R. D., Wiest, W. G., Allison, J. H., Polakoski, K., & Robins, E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504242921703 · Cited by 246
Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0929 · Cited by 236 · cited 2×
“Buprenorphine is preferable to methadone in terms of improved testosterone levels and sexual function [21, 22].”
BackgroundSymptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids
Rajagopal, A., Vassilopoulou‐Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2004) · Cancer · doi:10.1002/cncr.20028 · Cited by 206 · cited 2×
“LH and FSH levels have been shown to be increased in male cancer survivors [19], while the opposite has been found in cancer survivors on opioids, MEDD >200 mg [20].”
BackgroundSIMONS, J. P. F. H. A., SCHOLS, A. M. W. J., BUURMAN, W. A., & WOUTERS, E. F. M. (1999) · Clinical Science · doi:10.1042/cs0970215 · Cited by 156
Plasma testosterone levels in heroin addiction and during methadone maintenance.
Mendelson, J. H., Mendelson, J. E., & Patch, V. D. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30047-9 · Cited by 148
Daniell, H. (2006) · Journal of Pain · doi:10.1016/j.jpain.2006.04.011 · Cited by 144
Hypogonadism in patients treated with intrathecal morphine
Finch, P. M., Roberts, L. J., Price, L., Hadlow, N. C., & Pullan, P. T. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200009000-00011 · Cited by 144 · cited 1×
“This is in keeping with studies carried out in other patient groups [16–18].”
ResultOpen-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency
Daniell, H. W., Lentz, R., & Mazer, N. A. (2006) · The Journal of Pain · doi:10.1016/j.jpain.2005.10.009 · Cited by 135 · cited 1×
“There was no accompanying decrease in pain scores or opioid requirement [31].”
BackgroundThe impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors
Gerl, A., M�hlbayer, D., Hansmann, G., Wilfried, M. R. A. Z., & Hiddemann, W. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1297::aid-cncr1132>3.0.co;2-z · Cited by 128
Hypogonadism in men receiving methadone and buprenorphine maintenance treatment
Hallinan, R., Byrne, A., Agho, K., McMahon, C. G., Tynan, P., & Attia, J. (2009) · International Journal of Andrology · doi:10.1111/j.1365-2605.2007.00824.x · Cited by 124
Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women
Fraser, L.-A., Morrison, D., Morley-Forster, P., Paul, T., Tokmakejian, S., Larry Nicholson, R., Bureau, Y., Friedman, T., & Uum, S. H. M. V. (2008) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2008-1076715 · Cited by 112 · cited 1×
“Men with chronic non-malignant pain have been found to be more frequently affected by OIH than women [30].”
BackgroundStrasser, F., Palmer, J. L., Schover, L. R., Yusuf, S. W., Pisters, K., Vassilopoulou‐Sellin, R., DeGracia, B., Willey, J. S., & Bruera, E. (2006) · Cancer · doi:10.1002/cncr.22339 · Cited by 112 · cited 4×
“Both showed opioid consumption to be associated with reduced LH and FSH levels, with opioid dose inversely correlated with LH levels in the paper by Skipworth [6, 8].”
BackgroundInfluentialTHE EFFECT OF HEROIN ADDICTION ON PITUITARY‐TESTICULAR FUNCTION
WANG, C., CHAN, V., & YEUNG, R. T. T. (1978) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1978.tb03585.x · Cited by 109
Hypogonadism in male patients with cancer
Garcia, J. M., Li, H., Mann, D., Epner, D., Hayes, T. G., Marcelli, M., & Cunningham, G. R. (2006) · Cancer · doi:10.1002/cncr.21889 · Cited by 100
Greenfield, D., Walters, S. J., Coleman, R. E., Hancock, B. W., Eastell, R., Davies, H. A., Snowden, J. A., Derogatis, L. R., Shalet, S. M., & Ross, R. J. M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2744 · Cited by 100
Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy
Rajagopal, A., Vassilopoulou‐Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. D. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00331-2 · Cited by 95
Hypogonadism in male patients with metastatic cancer prior to chemotherapy.
Chlebowski, R. T., & Heber, D. (1982) · PubMed · Cited by 90
Mendelson, J. H., & Mello, N. K. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975175529 · Cited by 83
Kiserud, C. E., Fosså, A., Bjøro, T., Holte, H., Cvancarova, M., & Fosså, S. D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604892 · Cited by 71
Skipworth, R. J. E., Moses, A. G. W., Sangster, K., Sturgeon, C. M., Voss, A. C., Fallon, M., Anderson, R. A., Ross, J. A., & Fearon, K. C. H. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0832-y · Cited by 61
Self-citationMale hypogonadism associated with advanced cancer: a systematic review
Vigano, A. A. L., Piccioni, M., Trutschnigg, B., Hornby, L., Chaudhury, P. K., & Kilgour, R. D. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70021-8 · Cited by 60
Simons, J. P. F. H. A., Schols, A. M. W. J., Buurman, W. A., et al. (1999) · Clinical Science · doi:10.1042/cs19990021 · Cited by 56
Pangalis, G. A., Roussou, P. A., Kittas, C. N., Kokkinou, S., & Fessas, P. (1987) · Cancer · doi:10.1002/1097-0142(19870215)59:4<755::aid-cncr2820590415>3.0.co;2-j · Cited by 54
Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma.
Iversen, P., Rasmussen, F., & Christensen, I. J. (1994) · PubMed · Cited by 54
Menstrual cycle length during methadone maintenance
Schmittner, J., Schroeder, J. R., Epstein, D. H., & Preston, K. L. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01091.x · Cited by 51
Dev, R., Hui, D., Dalal, S., Nooruddin, Z. I., Yennurajalingam, S., Fabbro, E. D., & Bruera, E. D. (2011) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2010.06.021 · Cited by 45
Testosterone Levels and Quality of Life in Diverse Male Patients With Cancers Unrelated to Androgens
Fleishman, S. B., Khan, H., Homel, P., Suhail, M. F., Strebel-Amrhein, R., Mohammad, F., Mahajan, D., Rosenwald, V., Guarino, M. J., Mirzoyev, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3818 · Cited by 36
Pancreatic carcinoma and low serum testosterone; a correlation secondary to cancer cachexia?
Todd, B. (1988) · PubMed · Cited by 26
Rajagopal, A., & Bruera, E. D. (2003) · Pain Medicine · doi:10.1111/j.1526-4637.2003.03041.x · Cited by 16
Cited by
Opioids and their endocrine effects: a systematic review and meta-analysis
de Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz022 · Cited by 139
Opioid-induced endocrinopathies
Fountas, A., Van Uum, S., & Karavitaki, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30254-2 · Cited by 77
KotliÅ„ska-Lemieszek, A., & Zylicz, Z. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s342409 · Cited by 74
Rahmati, B., Moghaddam, M. G., Khalili, M., Enayati, E., Maleki, M., & Rezaeei, S. (2016) · PubMed Central · doi:10.22074/ijfs.2016.4915 · Cited by 22
Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement
Karavitaki, N., Bettinger, J. J., Biermasz, N., Christ-Crain, M., Gadelha, M. R., Inder, W. J., Tsourdi, E., Wakeman, S. E., & Zatelli, M. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae023 · Cited by 14
Metadata
- Authors
- McWilliams, K., Simmons, C., Laird, B. J., & Fallon, M. T.
- Affiliations
- Beatson West of Scotland Cancer Centre (GB)
- Western General Hospital (GB)
- Corresponding author
- McWilliams, Kerry
- Venue
- Supportive Care in Cancer
- Published
- 2014-03-15
- Volume
- 22
- Issue
- 6
- Pages
- 1699-1704
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2122727883
- Semantic Scholar
- 6e3edb441be16c3cc4807171741f85f8d5aa02c4
- Cited by
- 20
- References
- 34
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 5 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 1 · 2016: 1 · 2015: 4
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- opioids, hypogonadism, cancer patients, cancer pain, gonadal function, dose-dependent effects, survival, adverse drug reactions
- MeSH terms
- Analgesics, Opioid, Female, Gonads, Humans, Hypogonadism, Male, Neoplasms, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.